Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure

Sodium-glucose co-transporter 2 (SGLT2) receptors are primarily located in the proximal convoluted tubule of the nephron. These receptors are responsible for almost 90-95% of tubular reabsorption of the glucose in the nephron. In patients with diabetes mellitus (DM), due to upregulation of SGLT2 receptors, glucose reabsorption is further increased. The Food and Drug Administration (FDA) approved SGLT2 inhibitors, such as canagliflozin, empagliflozin, dapagliflozin, and ertugliflozin, for the treatment of type 2 diabetes.

Source: The American Journal of Cardiology - September 8, 2019 Category: Cardiology Authors: Raktim K Ghosh, Gopal Chandra Ghosh, Manasvi Gupta, Dhrubajyoti Bandyopadhyay, Tauseef Akhtar, Prakash Deedwania, Carl J Lavie, Gregg C Fonarow, Ashish Aneja Source Type: research